Twist Bioscience guides FY26 revenue at $442-$447 million

Twist Bioscience

Twist Bioscience

TWST

0.00
  • Twist Bioscience guided fiscal 2026 revenue of $442 million to $447 million, disclosed May 4, 2026.
  • The outlook implies growth from about $377 million of revenue in fiscal 2025.
  • The presentation also pointed to gross margin above 52% alongside the fiscal 2026 revenue guidance, versus 51% in fiscal 2025.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Twist Bioscience Corporation published the original content used to generate this news brief on May 21, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.